For a study, researchers looked at (1) the epidemiology and pathophysiology of pelvic organ prolapse (POP) and occult stress urinary incontinence (SUI), (2) data on combined surgical care of POP and occult SUI, (3) clinical decision-making techniques, and (4) future therapeutics. Many approaches to treating prolapse and occult stress urinary incontinence at the same time, such as minimally invasive sacrocolpopexy and mid-urethral sling, or older approaches that have regained favor among patients and clinicians who want to avoid synthetic mesh, such as native tissue prolapse repair and pubovaginal sling, had limited prospective data. Safe, long-lasting therapies using absorbable graft materials that generated a positive host response were fascinating, but practical adoption might be a long way off. Although stem cell therapy had shown promise in phase I/II studies for the treatment of stress urinary incontinence, it had not been explored in the context of concurrent treatment of occult SUI with POP surgery and was still in the preclinical stage for the treatment of POP.
A tailored approach to simultaneous SUI surgery that took into account individual risk factors as well as informed patient preferences was anticipated to improve the risk/benefit ratio and patient satisfaction. Novel therapeutics, including graft materials and cellular therapies that triggered a regenerative response, might enhance or maintain continence results while reducing risk and changing how POP and SUI operations were approached.
Reference:link.springer.com/article/10.1007/s11934-019-0885-5
